NEW YORK--(BUSINESS WIRE)--
Retrophin, Inc. (OTCQB: RTRX) today announced that it has elected
Cornelius ("Neal") E. Golding to its Board of Directors, effective
October 1, 2013. Mr. Golding will also serve as Chairman of the Audit
Committee. His appointment brings the Company's Board to four members.
Commenting on today's news, Martin Shkreli, Founder, President and Chief
Executive Officer of Retrophin, noted, "We are pleased to welcome Neal
to our Board of Directors and as Chairman of our Audit Committee. He
joins Retrophin at a critical time in the Company's life cycle. As such,
we expect to leverage his extensive knowledge base and expertise as we
pursue our operational and financial goals. This includes the continued
development and ultimate commercialization of our product pipeline, as
well as future financings and potential strategic acquisitions."
Mr. Golding brings to Retrophin more than 44 years of experience in
finance and accounting. Most recently, from August 1994 until his
retirement in September, 2003, he served as Senior Vice President and
Chief Financial Officer of Atlantic Mutual Insurance Company, where,
among other responsibilities, he oversaw the organization's corporate
investment portfolio. Before that, Mr. Golding spent 13 years in various
management and executive positions at Atlantic Mutual Insurance Company,
including Senior Vice President and Comptroller, Vice President and
Comptroller and Vice President-Internal Audit. Prior to that, he served
as Vice President of Ideal Mutual Insurance Company, Assistant
Controller of AIG, and in various positions at Crum & Forster. Earlier
in his career, Mr. Golding worked at the Robert Stigwood Organization
and as an auditor for the independent accounting firm of Price
Waterhouse (now PriceWaterhouseCoopers).
In addition to Retrophin, Mr. Golding currently serves on the Boards of
Directors of United Automobile Insurance Group and Hudson City Bancorp
(Chair of Risk Committee). He is also a Trustee of the John A. Forster
Trust. He previously served on the Board of Directors of Neurologix,
Inc., Somerset Hills Bancorp and National Atlantic Holding Corporation.
A graduate of St. John Fisher College, Mr. Golding holds an MBA from
Fairleigh Dickenson University and is also a graduate of the Advanced
Education Program at the Wharton School of the University of
Pennsylvania. He is a retired CPA, as well as a member of the American
Institute of CPAs and the New York State Society of CPAs.
Retrophin is a pharmaceutical company focused on the discovery and
development of drugs for the treatment of debilitating and often
life-threatening diseases for which there are currently no viable
patient options. The Company is currently focused on several
catastrophic diseases affecting children, including Focal Segmental
Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated
Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and others.
Retrophin's lead compound, RE-021, is scheduled to begin enrollment in a
potentially pivotal Phase 2 clinical trial for FSGS during 2013. For
additional information, please visit www.retrophin.com.
This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995,
regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them, and
could cause actual outcomes and results to differ materially from
current expectations. No forward-looking statement can be guaranteed.
Forward-looking statements in the press release should be evaluated
together with the many uncertainties that affect the Company's business.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Marc Panoff, CFO
Paula Schwartz (Investors)
Source: Retrophin, Inc.
News Provided by Acquire Media